The Technology Merck Bet $3 Billion On: Ingenia Returns to Fight on KOSDAQ

• Who Is Ingenia Therapeutics, the Company Merck Eyed Before It Even Listed
• From Eyes to Kidneys: The Firm That Made $3 Billion From an Antibody That Revives Broken Vessels
• What Happens If IGT-427's Phase 3 Succeeds, and Why You Should Watch Ingenia Now
• The CEO's Regret, "We Sold Too Early," and How He's Playing It Differently This Time
• KOSDAQ-Listed Ingenia: Its Real Value Was Never IGT-427

🩸 The Technology Merck Bet $3 Billion On: Ingenia Therapeutics' Real Play on the KOSDAQ

💡 Why This Company Deserves Your Attention Now

News of biotech IPOs floods in almost daily. Yet amid that deluge, one name stands out: Ingenia Therapeutics. The reason is surprisingly simple. Even before clearing the hurdle of going public, the company saw one of its drug candidates effectively acquired by MSD (Merck & Co. in the U.S.), one of the world's largest pharmaceutical firms.

Here is how it unfolded. In 2022, Ingenia licensed a candidate to EyeBio, a biotech specializing in ophthalmic diseases. Then in 2024, MSD acquired EyeBio for up to $3 billion, elevating the molecule Ingenia had created into a core development asset of a global pharma giant. Rather than the company simply proclaiming "our technology is excellent," a top-tier drugmaker actually paid a fortune to validate it. For context, the industry calls the collection of a company's drug candidates its "pipeline," a term drawn from the image of products flowing along a factory conveyor belt as each candidate advances through development stages one by one. This validated pipeline is where Ingenia's story begins.

At a press conference held on July 14 at the Conrad Hotel in Yeouido, Seoul, CEO Han Sang-yeol unveiled the company's technology and pipeline direction. The firm subsequently set its offering price at 12,000 won and now stands on the verge of a KOSDAQ listing on August 18.

🔬 The Core Technology: Not Building New Vessels, but Reviving Broken Ones

To truly grasp Ingenia, you only need to hold onto a single concept: TIE2.

The inner walls of our blood vessels are densely lined with cells called vascular endothelial cells. On the surface of these cells sits a protein that acts like an antenna and switch, relaying outside signals into the cell, and TIE2 plays exactly that role. When this switch turns on, blood vessels stay firm and stable; when it shuts off or weakens, vessels leak, inflammation spreads, and their structure collapses. Diseases that look entirely different on the surface, such as diabetic retinal disease, macular degeneration, and chronic kidney disease, actually share a single root: the breakdown of microvessels. And what governs that root is TIE2.

The name of Ingenia's antibody technology is "TIE-body." This antibody works by directly pressing and switching on TIE2. The word "directly" is the crux here.

Conventional approaches mostly took the roundabout route, removing substances that interfere with TIE2 in hopes the switch would turn on by itself, an indirect method. It's like trying to turn on a light not by pressing the switch but by clearing away an obstacle in front of it and hoping it presses itself. Ingenia, by contrast, presses the switch itself with precision. In principle, that means it can act more clearly and powerfully.

On top of this, the company holds another platform called LCIDEC, a dual-function antibody that turns on TIE2 while simultaneously pulling disease-causing harmful proteins into the cell to eliminate them. Whereas an ordinary antibody grabs just one target, an antibody that grabs two different targets at once, turning on what should be on and eliminating what should be gone, is called a bispecific antibody. The idea is to strike two problems at once with a single drug.

👁️ Flagship Candidate IGT-427: Blocking VEGF, Igniting TIE2

Ingenia's signature candidate is IGT-427 (MSD internal code name MK-8748). Its true value lies in handling two jobs at once.

First, it suppresses VEGF. VEGF is a signaling molecule that orders new blood vessels to form. It is essential under normal conditions, but in macular degeneration or diabetic retinopathy it pours out excessively, mass-producing fragile, leaky vessels. These flawed vessels cause fluid to pool in the eye (edema) and erode vision. That is why the current standard of ophthalmic care is the anti-VEGF injection, with products like Eylea and Lucentis being representative.

Second, IGT-427 does not stop at blocking VEGF; it directly ignites TIE2 as well. Conventional anti-VEGF injections merely prevent more bad vessels from forming, but they cannot restore vessels already worn down to fragility. IGT-427 adds TIE2 activation to fundamentally stabilize the vessels. It's like not just putting out a spreading fire but also reinforcing the charred framework of the structure.

This drug targets three diseases. One is wet (neovascular) age-related macular degeneration, or nAMD, a leading cause of blindness in old age caused by abnormal vessels growing in the retina. The second is diabetic macular edema (DME), in which fluid builds up in the central retina of diabetic patients. The third is branch retinal vein occlusion (BRVO), which occurs when one branch of a retinal vein becomes blocked. All three share the common root of leaking, collapsing microvessels.

The clinical data CEO Han presented is striking. In the early-stage Phase 1/2a trial, patients responded to the drug in just one week, retinal edema largely subsided, and after a month conditions had recovered to nearly normal levels. A Phase 1/2a trial refers to an early-stage study in humans examining safety and initial efficacy. Han emphasized, "The fact that efficacy appears this rapidly is precisely what EyeBio and MSD valued most."

The company said that when it compared its 12-week data against existing anti-VEGF treatments, it confirmed competitiveness in reducing central subfield thickness (CST), a measure of central retinal thickness, and in improving best-corrected visual acuity (BCVA), meaning vision corrected with glasses. It made clear, however, that the final verdict on efficacy and safety will be decided by the ongoing global Phase 3 trials. MSD is currently running two global Phase 3 trials, each enrolling 960 nAMD patients, across more than 140 clinical sites for a total of roughly 2,000 subjects. A Phase 3 trial is the largest and most expensive stage, testing real efficacy and safety in a large patient population just before approval. A big pharma pouring in resources on this scale is read as a sign of correspondingly high expectations.

🧠 An Often-Missed Angle: The Real Meaning Behind "We Sold Too Early"

At the press conference, Han let slip his inner thoughts: "We released IGT-427 too early. I regret that we didn't advance development a bit further before out-licensing it. The further you go into late-stage trials, the more favorable the contract terms."

It sounds like a mere afterword, but it is in fact the key that unlocks Ingenia's entire strategy. The value of a biotech drug rises exponentially as it advances through development stages. Selling at the preclinical stage, before human dosing, versus selling with Phase 2 data in hand can differ by several multiples in deal size, because the lower the failure risk, the more a buyer is willing to pay. Since IGT-427 was handed off at the preclinical stage, the company inevitably calculates that "had we held on just a bit longer, we'd have received far more."

And this painful lesson is woven directly into the strategy for the second pipeline. Investors should not overlook this point.

🫘 The In-House IGT-303: This Time, No Rush

IGT-303 is a candidate Ingenia is developing on its own rather than handing off. This time the target is not the eye but the kidney.

Inside the kidney sits a cluster of tiny blood vessels called the glomerulus, which filters blood and sends waste out through urine. When the glomerulus's vessels are damaged, proteins that should not pass through leak into the urine, and this is proteinuria. Proteinuria is a hallmark warning sign that the kidney is failing, and it is itself a link in a vicious cycle that further damages the kidney. IGT-303 aims to switch on TIE2 in glomerular endothelial cells to restore damaged microvessels and reduce proteinuria. A global Phase 2a trial is currently underway in Australia, New Zealand, and South Korea.

It's worth noting why IGT-303's approach is fresh. As Han explained, today's chronic kidney disease treatments largely focus on controlling blood pressure and blood sugar to slow the decline of kidney function, in other words, hitting the brakes to delay deterioration. IGT-303, by contrast, is built on the concept of repairing the broken vessels themselves, so when added to existing therapy it is hoped to further reduce proteinuria and push back the point at which dialysis or a kidney transplant becomes necessary. Dialysis, which uses a machine to filter blood in place of failed kidneys, significantly lowers patients' quality of life, so even delaying that point carries substantial medical and economic significance.

Here the lesson from IGT-427 emerges clearly. Han said, "We expect to secure Phase 2a data around early 2027. At that point we'll begin discussions with global pharma in earnest, but we won't push out-licensing right away." He added, "Given our post-listing funding capacity and clinical development capabilities, carrying late-stage trials forward on our own is also an option on the table." Since the first molecule was sold in haste without capturing full value, the plan for the second is to accumulate enough data to maximize negotiating leverage before selling, or to develop it all the way in-house to recover greater value. This is also the real purpose of this KOSDAQ listing.

💰 Where the IPO Proceeds Go: 50.8 Billion Won Is the Company's Tomorrow

Ingenia plans to raise a total of 63 billion won, combining a 60 billion won offering (based on the bottom of the price band) with a 3 billion won mandatory underwriting amount by the lead manager. The mandatory underwriting amount is a rule requiring the securities firm managing the listing to buy a certain volume, a safeguard against reckless listings. Net proceeds after issuance costs come to about 57.8 billion won, of which 50.8 billion won, the vast majority, flows into R&D.

Of that, 22 billion won is earmarked for clinical trials alone. The top priority is completing IGT-303's Phase 2a trial and securing efficacy data. This dovetails precisely with the strategy examined above: "To build data that gives us leverage, we need funds to run the trial all the way, and we'll raise that money from the market." The remaining funds go toward advancing another candidate, IGT-532, into the clinic and preparing follow-on trials for IGT-303.

⚖️ Questions Investors Should Ask Themselves

When judging this company, chasing only the glittering numbers on the surface risks misjudgment. Here are the questions that ought to be asked but rarely are.

First, does the fact that "MSD bought it" guarantee steady revenue for Ingenia? Licensing deals are typically structured around an upfront payment, milestones paid each time development clears a specific gate, and royalties tied to sales. Milestones are performance-based payments triggered by hitting markers like trial success or approval. If IGT-427 succeeds in Phase 3 and reaches the market, substantial milestones and royalties could flow to Ingenia, but if Phase 3 fails, much of that expected revenue vanishes. In short, one must coolly recognize that IGT-427 is already in someone else's hands, and its success is a variable Ingenia cannot control.

Second, as appealing as the direct-TIE2-activation approach is, its superiority has not yet been proven in large-scale Phase 3. The rapid early-trial response is certainly encouraging, but in ophthalmology there have been no shortage of cases where strong early results failed to show clear differentiation over existing treatments in Phase 3. Since the company itself acknowledges the real verdict comes in Phase 3, it is more accurate to view expectation and uncertainty as standing side by side until those results arrive.

Third, the fact that a U.S.-headquartered firm chose Korea's KOSDAQ is worth pondering. A company running global trials across multiple countries choosing KOSDAQ over Nasdaq suggests a strategic calculation about domestic biotech investment sentiment and Korea's valuation environment. How this choice ripples through the share price after listing is a task investors must weigh separately.

Fourth, the most fundamental question: does this company's true value lie not in the single product IGT-427 but in its "platform"? If the direct-TIE2-activation technology worked in the eye, it can keep extending, through the kidney (IGT-303), into other microvascular diseases. Whether this is a company with a "mold" that can repeatedly stamp out hits, rather than a one-off hit, will be the real yardstick for evaluating it over the long term. It is both the reason Ingenia's narrative is compelling and the reason it requires verification.

🎯 In Closing

Ingenia Therapeutics knocks on KOSDAQ's door carrying both a powerful calling card, "technology pre-validated by big pharma," and a learned strategy, "the first molecule sold too fast and left value on the table, so the second will fetch its full worth." It is a textbook yet fascinating biotech IPO, with clear strengths and unproven Phase 3 risk standing side by side. Ultimately the watch points boil down to two: whether the MSD-led Phase 3 of IGT-427 succeeds, and what data the in-house IGT-303 brings forward in early 2027. These two pendulums will decide Ingenia's future.